Patients With Metastatic Colorectal Cancer May Benefit From Waiting For RAS Mutation Test Results Before Adding Anti-Epidermal Growth Factor Receptor Treatment To Chemotherapy, Research Suggests.

Medscape (10/29, Davenport, Subscription Publication) reports researchers found in a retrospective analysis that “clinicians who treat patients with metastatic colorectal cancer can safely wait to receive results of RAS mutation status before adding anti...